Role of vosoritide drug on children's with achondroplasia

  • Ahmed tawfeeq ahmed Ministry of Education, Baghdad, Iraq.
  • dr.inas hazim University of Mustansiriya, College of Dentistry
  • Nibras hazim hameed University of Tikrit, College of Medicine.

Abstract

Achondroplasia is a genetic condition with an autosomal dominant inheritance pattern. It is caused by detrimental heterozygous FGFR3 gene mutations. Gain-of-function mutations in the FGFR3 gene impair chondrocyte differentiation and proliferation, which has a negative impact on the formation of new bone. Vosoritide, also known as voxzogo, is the first pharmacological intervention to receive approval for the treatment of achondroplasia. This therapeutic agent has been sanctioned for administration via at-home injections, which are to be performed under the supervision of a proficient nurse.

Keywords: Achondroplasia, Vosoritide, Metabolism, Dosage

Downloads

Download data is not yet available.

Author Biographies

Ahmed tawfeeq ahmed, Ministry of Education, Baghdad, Iraq.

Ministry of Education, Baghdad, Iraq.

dr.inas hazim, University of Mustansiriya, College of Dentistry

University of Mustansiriya, College of Dentistry

Nibras hazim hameed, University of Tikrit, College of Medicine.

University of Tikrit, College of Medicine.

References

1. Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14(1):1.
2. Pfeiffer KM, Brod M, Smith A, et al. Assessing physical symptoms, daily functioning, and wellbeing in children with achondroplasia. Am J Med Genet A. 2021;185(1):33–45.
3. Pfeiffer KM, Brod M, Smith A, Viuff D, Ota S, Charlton RW. Functioning and well-being in older children and adolescents with achondroplasia: a qualitative study. Am J Med Genet A. 2022;188(2): 454–62.
4. Aldhouse NVJ, Kitchen H, Johnson C, et al. Key measurement concepts and appropriate clinical outcome assessments in pediatric achondroplasia clinical trials. Orphanet J Rare Dis. 2022;17(1):182.
5. Shediac R, Moshkovich O, Gerould H, et al. Experiences of children and adolescents living with achondroplasia and their caregivers. Mol Genet Genomic Med. 2022;10(4):e1891.
6. Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146: 115872.
7. Lorne H, Newman CJ, Unger S. Is height important for quality of life in children with skeletal dysplasias? Eur J Med Genet. 2020;63(4): 103816.
8. McGraw SA, Henne JC, Nutter J, Larkin AA, Chen E. Treatment goals for achondroplasia: a qualitative study with parents and adults. Adv Ther. 2022;39(7):3378–91.
9. Ireland P. O’Donaghey S. Development of Australian children with achondroplasia. Journal of Developmental and Behavioural Paediatrics. 2007; 31(1): 41-7.
10. European Medicines Agency. Voxzogo 2022 [updated 2022 February]. https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo. Accessed 13 Mar 2023.
11. U.S. Food and Drug Administration. Highlights of prescribing information. VOXZOGO (vosoritide) for injection, for subcutaneous use. Accessed August 8, 2022.
12. Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and exposureresponse of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022;61(2):263-280.
13. Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growthpromoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021;23(12):2443-2447.
Published
21-02-2024
Statistics
59 Views | 33 Downloads
Citatons
How to Cite
ahmed, A. tawfeeq, dr.inas hazim, and N. hazim hameed. “Role of Vosoritide Drug on children’s With Achondroplasia”. World Journal of Current Medical and Pharmaceutical Research, Vol. 6, no. 1, Feb. 2024, pp. 9-12, doi:10.37022/wjcmpr.v6i1.311.
Section
Review Articles